News

And the winners are...

SAN FRANCISCO, October 12, 2021 - UCSF Health Hub and UCSF Health Hub Awards committee is proud to announce the 20 winning companies and Hall of Fame inductees for the 2021 UCSF Health Awards. The winning UCSF companies include: Best of UCSF DNA - Companies with Product: Genentech Best of UCSF...

UCSF Founded NewCo, Erasca, Announces First Patient Dosed in HERKULES-2

UCSF technology founded NewCo, Erasca, a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced dosing of the first patient in the 

Catalyst Awardees Win the Harrington Innovator-Scholar Award

Jennifer Chen and John Chorba, two UCSF Catalyst awardees, win the 2021 Harrington Innovator-Scholar Award for projects that also won the Catalyst Award. MORE

FDA Accepts Epygenix Therapeutics IND to Initiate a Clinical Trial

Epygenix Therapeutics, Inc. ("Epygenix"), a clinical-stage biopharmaceutical company focused on rare and intractable genetic epilepsy, announced today that the U.S.

eFFECTOR Debuts as Publicly Traded Next-Generation Oncology Company

eFFECTOR Therapeutics, a clinical-stage biotech company co-founded by University of California Professor of 
Urology Davide Ruggero and Cellular and Molecular Pharmacologist Kevan Shokat, today completed its business combination with Locust Walk Acquisition Corp. eFFECTOR Therapeutics expects its...

Encellin Closes $5.9M Seed Financing

Encellin, a personalized regenerative medicine biotech company, founded at the University of California San Francisco (UCSF), and developing novel cell-based approaches to deliver sustained therapies with a single implant, today announced the closing of a $5.9M Seed financing round. The round was...

UCSF Health Awards Returns for 3rd Year and Includes Life Sciences Awards

Preview Video Link for the Award Show can be viewed here

Sonoma Biotherapeutics Raises $265M

Biotech company Sonoma Biotherapeutics has raised $265 million in new funding, the company announced Wednesday. The funding will be used to advance its programs aiming to treat autoimmune and inflammatory conditions such as rheumatoid arthritis and type 1 diabetes.

Epygenix Therapeutics to Proceed With Trial for the Treatment of Dravet Syndrome

Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on rare and intractable genetic epilepsy that uses UCSF technology developed by Dr. Scott Baraban, is pleased to announce that the company's ARGUS trial with EPX-100 (Clemizole Hydrochloride) in patients with Dravet syndrome...

RxSight sets terms for $125 million IPO

RxSight, a commercial med-tech company based on UCSF post-cataract intraocular lens technology, announced terms for its IPO on Monday. The company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18.  MORE